2024-12-20 - Analysis Report
## Eli Lilly and Co. (LLY) Stock Analysis Report

This report analyzes Eli Lilly and Co. (LLY), a pharmaceutical company, based on the provided data.  Note that this analysis is solely based on the provided data and may not reflect a complete picture.

**1. Performance Comparison with S&P 500 (VOO):**

LLY has significantly outperformed the S&P 500 (VOO).  The cumulative return for LLY is 546.73%, while VOO's is 114.28%.  The difference in cumulative returns is a substantial 432.4%, placing it at the 69.3rd percentile of the historical range of the difference between the two.  This indicates LLY's strong performance relative to the broader market. The provided CAGR data further supports this, showing consistently high growth rates exceeding that of the market index.

**2. Recent Price Movement:**

* **Closing Price:** $757.54
* **5-Day Moving Average:** $773.80
* **20-Day Moving Average:** $788.58
* **60-Day Moving Average:** $836.38

The current price is below all three moving averages, suggesting a potential downward trend in the short to medium term.  This warrants caution.

**3. Technical Indicators and Expected Return:**

* **RSI (Relative Strength Index):** 34.57.  This suggests the stock is potentially oversold, but it's important to note that RSI alone isn't a conclusive indicator.
* **PPO (Price Oscillator):** -0.235.  A negative PPO indicates bearish momentum.
* **20-Day Relative Divergence:** -2.3%.  Indicates a recent short-term downward trend.
* **Expected Return:** 584.4%. This is a high expected return relative to the S&P 500, suggesting significant outperformance is projected over the long term (2+ years) assuming continued performance at this level.  However, this projection is based on past performance and shouldn't be taken as a guarantee.  Significant risk is inherent with this type of investment strategy.
* **Price Impact:** The current price ($757.54) is below recent moving averages, suggesting a price decline rather than a sharp rebound or drop.

**4. Recent Earnings Analysis:**

The provided earnings data shows some volatility:

* **Revenue:**  Revenue fluctuates, with a recent peak in Q3 2024, but overall shows a positive trend.
* **EPS (Earnings Per Share):**  Significant fluctuations are observed in EPS. Q2 2024 shows a substantial increase compared to other quarters, but Q4 2024 and Q4 2023 show negative EPS values, requiring further investigation to understand underlying causes.  The provided data does not give any context of expectations, so it is difficult to analyze beats or misses.

**5. Financial Information:**

* **Revenue and Profitability:** Revenue is relatively stable, with minor fluctuations across quarters. Profit margins remain consistently high (around 80%).
* **Capital and Profitability:**  Equity shows a growth trend. ROE (Return on Equity) exhibits significant quarter-to-quarter variation, notably a negative ROE in Q3 2023, followed by a significant increase in Q2 2024. This volatility requires deeper analysis to understand the underlying drivers.

**6. News and Recent Issues:**

No specific news or recent market outlook or analyst opinions are provided in the initial data set.

**7. Overall Analysis:**

LLY has demonstrated exceptional performance relative to the S&P 500, showing significantly higher cumulative returns and CAGR. However, recent price action suggests a potential short-term downward trend. Technical indicators (RSI and PPO) show mixed signals. While the expected long-term return is high, the volatility in EPS and ROE warrants caution.  More information is needed regarding news, analyst opinions, and the context of beats/misses on earnings expectations to complete a comprehensive analysis. The provided data displays strong performance historically but also exhibits some recent short-term weakness and earnings volatility.  Further investigation into the specifics of the company's performance and market conditions would be essential to a more conclusive analysis.

**8. Disclaimer:** This analysis is for informational purposes only and should not be considered investment advice.  Investing in the stock market involves significant risk, and past performance is not indicative of future results.  Consult with a financial advisor before making any investment decisions.
